Secondary Logo

Journal Logo

CME Information

JAIDS Journal of Acquired Immune Deficiency Syndromes: September 1st, 2008 - Volume 49 - Issue - p S75-S76
doi: 10.1097/QAI.0b013e3181864efe
CME
Free
Back to Top | Article Outline

TARGET AUDIENCE

This activity has been designed to meet the educational needs of physicians and other health care professionals involved in the management of patients with HIV.

Back to Top | Article Outline

PROGRAM OVERVIEW

The success of highly active antiretroviral therapy (HAART) has resulted in the long-term survival of many patients who are infected with HIV. However, this positive result is accompanied by an increased risk for the development of conditions that arise either directly from protracted therapy or from factors that all members of the population are exposed to as they age. Both contribute to the increased cardiometabolic risk experienced by patients under long-term treatment for HIV infection. Insulin resistance, glucose intolerance, and diabetes are increasingly reported in patients receiving antiretroviral therapy, as well as lipodystrophy, characterized by changes in fat mass, and lipid abnormalities, arising primarily from the effects of specific HAART components. This program will review the pathogenesis of antiretroviral-associated metabolic abnormalities, examine the associated increase in cardiovascular risk that occurs during antiretroviral therapy, explore the management of different cardiometabolic complications once they occur, and examine evidence regarding prevention of these abnormalities.

Back to Top | Article Outline

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

  • Assess the overall risk of metabolic dysfunction attributed to traditional risk factors, HIV infection, and HAART.
  • Describe the epidemiology and pathogenesis of treatment-related metabolic complications experienced by patients infected with HIV.
  • Recognize the risk for metabolic complications and the associated cardiovascular liability of specific components of HAART.
  • Identify appropriate treatments for the clinical management of metabolic complications associated with the use of antiretrovirals.
Back to Top | Article Outline

ACTIVITY CHAIRPERSON

Pablo Tebas, MD

Associate Professor of Medicine

Principal Investigator

AIDS Clinical Trials Unit

University of Pennsylvania

Philadelphia, PA

Back to Top | Article Outline

FACULTY

Todd T. Brown, MD, PhD

Assistant Professor of Medicine

Division of Endocrinology and Metabolism

The Johns Hopkins University

Baltimore, MD

Donald P. Kotler, MD

Professor of Medicine

Director, Division of Gastroenterology

College of Physicians and Surgeons

Columbia University

St. Luke's-Roosevelt Hospital Center

New York, NY

David A. Wohl, MD

Associate Professor of Medicine, AIDS Clinical Trials Unit

University of North Carolina

Chapel Hill, NC

Back to Top | Article Outline

ACCREDITATION STATEMENT

SciMed is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Back to Top | Article Outline

CREDIT DESIGNATION

SciMed designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Back to Top | Article Outline

DISCLOSURE AND RESOLUTION OF CONFLICTS OF INTEREST

SciMed assesses conflicts of interest with its faculty and all individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are resolved by SciMed to ensure fair balance and scientific objectivity.

When asked to report any potential conflict(s) of interest, faculty reported the following:

Todd T. Brown, MD, PhD

Grants/Research Support: Abbott Laboratories and Theratechnologies Inc.

Consultant: EMD Serono, Inc.

Donald P. Kotler, MD

Grants/Research Support: EMD Serono, Inc, Gilead Sciences, Roche Pharmaceuticals, and Theratechnologies Inc.

Consultant: Bristol-Myers Squibb Company, EMD Serono, Inc, Gilead Sciences, Theratechnologies Inc, and Vertex Pharmaceuticals, Inc.

Speakers Bureau: Abbott Laboratories, Bristol-Myers Squibb Company, EMD Serono, Inc, and Gilead Sciences.

Pablo Tebas, MD

Grants/Research Support: Boehringer Ingelheim, Bristol-Myers Squibb Company, GlaxoSmithKline, Merck & Co., Inc., Pfizer Inc, Roche Pharmaceuticals, Schering-Plough, Tibotec Pharmaceuticals Limited, VGX Pharmaceuticals Inc., and VIRxSYS.

Consultant: Boehringer Ingelheim, Bristol-Myers Squibb Company, Merck & Co., Inc., Tibotec Pharmaceuticals Limited, and VGX Pharmaceuticals Inc.

David A. Wohl, MD

Grants/Research Support: Abbott Laboratories, Merck & Co., Inc., and Roche Pharmaceuticals.

Speakers Bureau: Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb Company, Gilead Sciences, Merck & Co., Inc., Roche Pharmaceuticals, and Tibotec Pharmaceuticals Limited.

All SciMed personnel involved in the development of content for this activity have no relevant conflicts to report.

The materials for this activity were peer reviewed by Sandra Knoll, MD, Assistant Director, Lankenau Hospital Clinical Care Center. Dr Knoll has no relevant conflicts to report.

Back to Top | Article Outline

INSTRUCTIONS FOR OBTAINING CME CREDIT

There are no fees for participating in and receiving CME credit for this activity. To obtain CME credit for participating in this activity during the period September 1, 2008, through September 1, 2009, participants must (1) read the educational objectives and disclosure statements, (2) study the educational activity, (3) complete the posttest by recording the best answer to each question, (4) complete the evaluation form, and (5) mail or fax the evaluation form with answer key to SciMed per the instructions on the form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 80% or better. Participants will be mailed a certificate or statement of credit within 4-6 weeks.

Back to Top | Article Outline

DISCLAIMER

The opinions or views expressed in this CME activity are those of the presenters and do not necessarily reflect the opinions or recommendations of SciMed or the commercial supporter. Participants should critically appraise the information presented and are encouraged to consult appropriate resources for information surrounding any product, device, or procedure mentioned.

© 2008 Lippincott Williams & Wilkins, Inc.